title: [New drug development by innovative drug administration--"change" in pharmaceutical field].
abstract: New drug development can be made by providing products of higher "selectivity for the drug" for medical treatment. There are two ways for the approach to get higher "selectivity of drug": 1) discovery of new compounds with high selectivity of drug; 2) innovation of new drug administration, that is new formulation and/or method with high selectivity of drug by integration and harmonization of various hard/soft technologies. An extensive increase of biological information and advancement of surrounding science and technology may modify the situation as the latter overcomes the former in the 21 century. As the science and technology in the 21 century is said to be formed on "3H", that is, 1. hybrid; 2. hi-quality; 3. husbandry, the new drug development by innovative drug administration is exactly based on the science and technology of 3H. Its characteristic points are interdisciplinary/interfusion, international, of philosophy/ethics, and systems of hard/hard/heart. From these points of view, not only the advance of unit technology but also a revolution in thinking way should be "must" subjects. To organize this type of research well, a total research activity such as ROR (research on research) might take an important and efficient role. Here the key words are the "Optimization technology" and "Change in Pharmaceutical Fields." As some examples of new drug innovation, our trials on several topical mucosal adhesive dosage forms and parenteral administration of peptide drugs such as insulin and erythropoietin will be described.
authors.affiliation: Department of Pharmaceutics, Hoshi University, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nagai
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004304:Dosage Forms; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D004921:Erythropoietin / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D008081:Liposomes; D008863:Microspheres; D013678:Technology, Pharmaceutical
chemical_list: D004304:Dosage Forms; D004337:Drug Carriers; D007328:Insulin; D008081:Liposomes; D004921:Erythropoietin